A Prospective Open-Label Trial of a CBD/THC Cannabis Oil in Dravet Syndrome

Annals of Clinical and Translational Neurology - United States
doi 10.1002/acn3.621
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2005English

Rheopheresis in Patients With Ischemic Diabetic Foot Syndrome: Results of an Open Label Prospective Pilot Trial

Therapeutic Apheresis and Dialysis
HematologyNephrology
2003English

Tinkering With THC-to-CBD Ratios in Marijuana

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2018English

Periphere Neuropathische Schmerzen: THC / CBD-Spray Wirksam

Journal Club Schmerzmedizin
2015English

Open-Label Placebo Treatment of Women With Premenstrual Syndrome: Study Protocol of a Randomised Controlled Trial

BMJ Open
Medicine
2020English

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

New England Journal of Medicine
Medicine
2017English

CBD Oil

British Dental Journal
Dentistry
2020English

Long-Term Follow-Up in an Open-Label Trial of Triheptanoin in GLUT1 Deficiency Syndrome: A Sustained Dramatic Effect

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

Cytokine IL1α and Lactate as Markers for Tissue Damage in Spineboard Immobilisation. A Prospective, Randomised Open-Label Crossover Trial

Journal of the Mechanical Behavior of Biomedical Materials
Mechanics of MaterialsBiomedical EngineeringBiomaterials
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy